UK pharmaceuticals giant GlaxoSmithKline has unveiled an “open innovation” platform through which it will publish data from its clinical trials online so it can be analysed by external researchers.
The online system allows scientists to submit a to request access anonymised drug trial data. Each request will be judged a panel of external experts appointed by GSK, and applicants must agree to publish their own findings.
{iframe}http://www.information-age.com/it-management/strategy-and-innovation/123457031/glaxosmithkline-unveils-drug-trial-data-sharing-portal{/iframe}